<DOC>
	<DOCNO>NCT03032211</DOCNO>
	<brief_summary>1 . Summary Clinical Investigation A summary clinical investigation provide include primary objective study , safety feasibility endpoint , number subject enrol , study duration , subject follow-up inclusion/exclusion criterion . 1 . Primary Objective The primary objective study evaluate safety feasibility alfapump® System indication use management fluid NYHA Class III ambulatory NYHA Class IV heart failure patient eGFR &gt; 15 &lt; 60 mL/min/1.73m2 . 2 . Study Endpoints 1 . Primary Safety Endpoint The primary safety endpoint assessment occurrence adverse event ( AEs ) serious adverse event ( SAEs ) relate : 1 . Surgical implant alfapump® 2 . Device malfunction 3 . Dialysate infusion 2 . Secondary Safety Endpoints The secondary endpoint assessment : 1 . Time first hospitalization relate fluid management activation alfapump® System initiation dialysate infusion occur 2 . Rate occurrence re-hospitalizations related fluid management 3 . All-cause mortality 3 . Assessment Feasibility Fluid Management Heart Failure Indication The feasibility alfapump® System management fluid NYHA Class III ambulatory NYHA Class IV heart failure patient renal dysfunction assess net fluid balance measure ability alfapump® System move fluid bladder dialysate instill .</brief_summary>
	<brief_title>Optimal Balance Alfapump® System Feasibility Study</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion Criteria Males females ≥ 18 year &lt; 80 year age Patients exhibit physical sign excessive fluid retention ( i.e . elevate JVD , peripheral edema , ascites , pulmonary edema , weight gain etc . ) Patients eGFR Modification Diet Renal Disease ( MDRD ) &gt; 15 &lt; 60 mL/min/1.73m2 Patients brain natriuretic peptide ( BNP ) ≥ 150 pg/mL and/or Nterminal prohormone brain natriuretic peptide ( NTproBNP ) ≥ 600 pg/mL time screen BNP ≥ 100 pg/mL and/or NTproBNP ≥ 400 pg/mL Patients Six Minute Walk Test ( SMWT ) exercise capacity 100 400 meter Patients present NYHA Class III ambulatory NYHA Class IV heart failure optimal medical management ( OMM ) base current heart failure practice guideline fail respond tolerate one follow intervention : 1 . Treatment diuretic therapy 2 . Treatment angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) least 30 day 3 . Treatment nitrate and/or vasodilator investigator 's discretion 4 . Treatment betablockers least 90 day 5 . Treatment cardiac resynchronization therapy ( CRT ) 6 . Treatment automatic implantable cardioverter defibrillator ( AICD ) Patients demonstrate compliance current medical regimen report treat physician Enrollment Exclusion Criteria Patients present acute decompensated heart failure require hospitalization management symptom ( i.e . hospitalization exacerbation chronic heart failure manifest sign symptom require intravenous and/or aggressive therapy ) Patients ascites physical examination result predominantly right heart failure Patients indication candidate CRT treat CRT Patients indication candidate AICD implant AICD Patients reversible cause heart failure may remedied conventional surgery intervention Patients eGFR MDRD &lt; 15 &gt; 60 ml/min/1.73m2 Patients body mass index ( BMI ) &lt; 18 kg/m2or &gt; 35 kg/m2 Patients severe pulmonary disease history ( i.e . severe chronic obstructive pulmonary disease , severe hypoxia pulmonary artery mean pressure &gt; 40 mm Hg ) Patients experienced myocardial infarction ( MI ) within past 90 day Patients experience cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within past 90 day Patients undergone cardiac surgery major surgery within past 90 day Patients candidate require concomitant surgical procedure [ i.e . coronary artery bypass graft ( CABG ) , valvular surgery , etc . Patients candidate require temporary durable mechanical circulatory support [ i.e . intraaortic balloon pump ( IABP ) , ventricular assist device ( VAD ) , extracorporeal membrane oxygenation ( ECMO ) ] Patients confirm untreated abdominal aortic aneurysm ( AAA ) &gt; 5 cm diameter diagnose within past six month Patients active systemic uncontrolled infection Patients pregnant ( Note : Negative pregnancy test require woman Patients know alcohol illicit drug abuse dependence within previous three month Patients currently enrol participate past 30 day another therapeutic and/or interventional clinical study Patients technical obstacle pose inordinately high surgical risk judgment Investigator Patients underlying condition , opinion Investigator , would disqualify patient inclusion study , limit survival less one year , permit valid consideration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>